The past 60 years have seen huge advances in many of the scientific, technological and
managerial factors that should tend to raise the efficiency of commercial drug research and …

Background Treatment options for women presenting with triple negative breast cancer
(TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with …

Background Olaparib (AZD2281) is a small-molecule, potent oral poly (ADP-ribose)
polymerase (PARP) inhibitor. We aimed to assess the safety and tolerability of this drug in …

The last decade has brought a breakthrough in the knowledge of the biology of breast
cancer. The technological development, and in particular the high throughput technologies …

Triple‐negative breast cancer (TNBC) is a heterogeneous disease; gene expression
analyses recently identified 6 distinct TNBC subtypes, each of which displays a unique …

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial
ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease …

Inhibition of poly (ADP-ribose) polymerase (PARP) enzymes is a potential synthetic lethal
therapeutic strategy in cancers harbouring specific DNA-repair defects, including those …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a
heterogeneous disease, not only on the molecular level, but also on the pathologic and …

Triple-negative breast cancer (TNBC) is a heterogeneous disease; gene expression
analyses recently identified six distinct TNBC subtypes, each displaying a unique biology …

Purpose To identify optimal chemo-and targeted therapy for women with human epidermal
growth factor 2 (HER2)–negative (or unknown) advanced breast cancer. Methods A …